Work

A Phase I Dose Defining Study for MK-2206 Combined with Gefitinib in NSCLC Population Enriched with EGFR Mutation

Year: 2015

Type: article

Source: Annals of Oncology

DOI: 10.1093/annonc/mdv090.12

Authors: C.-C. Lin, C.-J. Yu, C.-C. Ho, K.-Y. Chen, J.-Y. Shih, Z.-Z. Lin, Y.-L. Lin, W.-Y. Liao, S.-H. Tsai, L. Yan, J. C.-H. Yang

Institution: National Taiwan University Hospital

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W2132085003

FWCI:

Cites:

Cited by: 2

Related to: 10